Clinical outcomes of multidrug-resistant organism infections in a tertiary care hospital in India

Table 1 Age-wise distribution of duration of hospital stay among isolated and non-isolated patients

Duration of hospital stay (days)	Non-ICU	ICU-isolated	ICU-non-isolated	Total
≤ 7	254	10	42	306
8-14	293	21	52	366
15-21	205	25	52	282
22-28	128	13	36	177
29-42	143	32	67	242
43-60	102	21	29	152
> 60	34	21	18	73
Total	1159	143	296	1598

ICU: Intensive care unit.

Table 2 Relationship between duration of hospital stay and presence of comorbidities

Range of hospital stay (days)	Presence of comorbidities
	Yes	No
≤ 3	30	46
4-10	142	251
11-25	166	438
26-50	94	289
51-100	33	102
> 100	1	6
Total	466	1132

χ² (5, n = 1598) = 20.1, P = 0.001.

Table 3 Relationship between department of admission and outcome of participants

Department	Outcome
	Discharge	Death	LAMA	Total
Neurology	44	11	4	59
Nephrology	64	5	1	70
Neurosurgery	126	42	6	174
General surgery	187	42	6	235
Trauma surgery	175	36	10	221
Pulmonary medicine	65	27	7	99
Gastroenterology	12	5	0	17
Emergency medicine	40	26	18	84
Otorhinolaryngeology	16	18	1	35
Internal medicine	186	55	19	260
Medical hematology-oncology	73	11	2	86
Surgical oncology	16	2	1	19
Pediatrics	12	3	2	17
Radiation oncology	11	0	0	11
Physical medicine & rehabilitation	2	0	0	2
Cardiology	25	0	1	26
Urology	27	2	1	30
Burns & plastic surgery	11	1	0	12
Obstetrics & gynaecology	26	3	3	32
Dermatology	3	0	0	3
Endocrinology	2	1	0	3
Geriatric medicine	5	2	0	7
Cardiothoracic and vascular surgery	2	0	0	2
Orthopaedics	8	4	0	12
Neonatology	1	3	0	4
Surgical gastroenterology	2	3	0	5
Radiotherapy	5	1	0	6
Medicine-intensive care unit	29	30	8	67
Total	1175	333	90	1598

χ² (54, n = 1598) = 177, P < 0.001. LAMA: Left-against medical advice.

Table 4 Duration of treatments of various antibiotic classes used

Class of antibiotic	DOT
Aminoglycosides	1413
Anthelmintic	71
Antifungal: Antimetabolite	79
Antifungal: Azole	804
Antifungal: Echinocandin	299
Antifungal: Polyene	449
Antimalarial	16
Antitubercular drugs	2455
Antiviral: Direct-acting antivirals	40
Antiviral: HAART	189
Antiviral: Neuraminidase inhibitors	114
Antiviral: NS5 polymerase inhibitors	92
Antiviral: Nucleoside analogue	285
Beta lactamase inhibitor	4452
Carbapenems	4587
Cephalosporins	3279
Fluoroquinolones	1640
Folic acid synthesis Inhibitors	910
Glycopeptides	2728
Lincosamides	604
Macrolide	562
Monobactam	169
Nitrofurans	195
Nitroimidazoles	1393
Other antibiotics (unknown)	1465
Oxazolidonones	1243
Penicillins	3907
Phosphonates	64
Polymixins	2322
Rifamycins	956
Tetracyclines	1229

DOT: Duration of treatments; HAART: Highly active antiretroviral therapy.